In 2023, Hawaii had the lowest death rate from cancer among all U.S. states, with around 119 deaths per 100,000 population. The states with the highest cancer death rates at that time were Kentucky, West Virginia, and Mississippi. This statistic shows cancer death rates in the United States in 2023, by state.

The graph displays cancer mortality rates by gender in the United States from 1999 to 2023. The x-axis represents the years, labeled from '99 to '23, while the y-axis indicates the mortality rates per 100,000 population for males, females, and the total population. Over this 24-year span, male mortality rates declined from a high of 252.8 in 1999 to a low of 165.4 in 2023. Female mortality rates decreased from 167.2 in 1999 to 123.6 in 2023. The total mortality rate dropped from 200.7 in 1999 to 141.5 in 2023. The data shows a consistent downward trend in cancer mortality rates for both genders and overall. The graph is presented in a line chart format, highlighting the yearly changes and trends in cancer mortality by gender.

In 2025, it was estimated that there would be over 972 thousand new cancer cases among women in the United States. This statistic illustrates the estimated number of new cancer cases and deaths in the United States for 2025, by gender.

The graph illustrates the number of deaths from cancer in the United States over the period from 1999 to 2023. The x-axis represents the years, labeled with two-digit abbreviations from '99 to '23, while the y-axis displays the annual number of cancer-related deaths. Throughout this 25-year span, the number of deaths ranges from a minimum of 549,829 in 1999 to a maximum of 613,349 in 2023. The data shows a gradual increase in annual deaths over the years. Notably, the number surpassed 550,000 in 2000 with 553,080 deaths, reached 574,738 in 2010, and exceeded 600,000 in 2020 with 602,347 deaths. The figures continued to rise, culminating in the highest recorded number of 613,349 deaths in 2023.

In 2023, there were around **** deaths from prostate cancer per 100,000 population in the state of Mississippi, making it the state with the highest prostate cancer death rate that year. This statistic shows the death rate from prostate cancer in the U.S. in 2023, by state.

In 2023, there were **** deaths from breast cancer per 100,000 population in the state of South Dakota, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2023, by state.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2023, the death rate from breast cancer was **** per 100,000 population. However, cancer is a serious public health issue in the United States and is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women have the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

In 2023, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2023.

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in United States was reported at 13.7 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on October of 2025.

This dataset contains the raw files exported from the CDC-WONDER database, and selections needed on the CDC-WONDER Multiple Causes of Death database in order to access and replicate our data and findings.

IntroductionDespite advancements in cervical cancer screening and HPV vaccines, demographic disparities perpetuate the burden of cervical cancer. The aim of this study is to utilize the most up-to-date CDC WONDER data of cervical cancer mortality to provide a comprehensive temporal analysis of demographic variables and account for patients missed in other database studies. In doing so, temporal trends found in this study may be used to guide future efforts and studies to understand nuanced barriers to cervical cancer screening and prevention.MethodsWith CDC WONDER Data, cervical cancer-related mortality was assessed in the U.S. from 1999 to 2023. Using age-adjusted mortality rates (AAMR), temporal trends were analyzed using the Joinpoint Regression Program for women 25 years and older across race, census regions, urban/rural residence, and states. Annual percentage change (APC) and average annual percentage change (AAPC) were calculated with 95% confidence intervals.ResultsCervical cancer-related mortality declined over the study period with an AAPC of –1.043*. Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. Region and race analysis demonstrated Black or African American patients in the Northeast held the largest decline in AAMR [AAPC of –3.218* (95% CI –3.708 to –2.390)], while Hispanic or Latino and Black or African American patients in the South closely followed AAPC of –1.347* (–1.898 to –0.824) and –2.656* (95% CI –2.939 to -2.350), respectively]. Rural areas (NonCore and Micropolitan) and the Southern region displayed a concerning positive trend after 2009 and 2010, though not statistically significant [APC values of 0.772 (95% CI -0.328 to 4.888), 0.986 (95% CI –0.252 to 4.887), and 0.286 (95% CI –0.061 to 0.772), respectively].ConclusionThese findings underscore the need for targeted interventions with consideration of regional and racial temporal disparities in cervical cancer-related mortality.

This statistic shows the percentage changes in selected causes of death due to diseases in the United States, between 2000 and 2022. The number of deaths caused by prostate cancer increased by 7.4 percent during this period. Changes in selected causes of deathThere has been a decrease in the rate of death caused by many diseases, including stroke and heart disease. However, the mortality rate due to Alzheimer’s disease increased by 142 percent from 2000 to 2022. Alzheimer’s disease caused 27.7 deaths per 100,000 population in 2023, making it the sixth leading cause of death in the United States. Mortality rates due to different diseases vary by different factors, including race and ethnicity. For example, cancer is the leading cause of death among Asians and Pacific Islanders in the United States, accounting for 22 percent of total deaths among this population, while heart disease is the leading cause of death among the white population. Ischemic heart disease is the leading cause of death worldwide, accounting for around nine million deaths in 2021. In the early 1900's, the mortality rate was primarily concentrated among people of younger ages, but increasingly, this has shifted to older population groups. In recent years, decreased mortality rates are often linked to improved medical care, such as new developments in medical technologies. Shifts in lifestyle habits such as decreased smoking rates and healthier diets may also attribute to lower mortality rates.

This dataset originates from the American Cancer Societyhttps://cancerstatisticscenter.cancer.org/module/c23c2QoY

In the period 2019 to 2023, the death rate for prostate cancer among Hispanic Americans was **** per 100,000 population. This statistic shows the death rate for prostate cancer among U.S. males from 2019 to 2023, by race and ethnicity.

In 2023, the states with the highest death rates due to heart disease were Oklahoma, Mississippi, and Alabama. That year, there were around 251 deaths due to heart disease per 100,000 population in the state of Oklahoma. In comparison, the overall death rate from heart disease in the United States was 162 per 100,000 population. The leading cause of death in the United States Heart disease is the leading cause of death in the United States, accounting for 22 percent of all deaths in 2023. That year, cancer was the second leading cause of death, followed by unintentional injuries and cerebrovascular diseases. In the United States, a person has a one in six chance of dying from heart disease. Death rates for heart disease are higher among men than women, but both have seen steady decreases in heart disease death rates since the 1950s. What are risk factors for heart disease? Although heart disease is the leading cause of death in the United States, the risk of heart disease can be decreased by avoiding known risk factors. Some of the leading preventable risk factors for heart disease include smoking, heavy alcohol use, physical inactivity, an unhealthy diet, and being overweight or obese. It is no surprise that the states with the highest rates of death from heart disease are also the states with the highest rates of heart disease risk factors. For example, Oklahoma, the state with the highest heart disease death rate, is also the state with the sixth-highest rate of obesity. Furthermore, Mississippi is the state with the highest levels of physical inactivity, and it has the second-highest heart disease death rate in the United States.

The leading causes of death in the United States have changed significantly from the year 1900 to the present. Leading causes of death in 1900, such as tuberculosis, gastrointestinal infections, and diphtheria have seen huge decreases in death rates and are no longer among the leading causes of death in the United States. However, other diseases such as heart disease and cancer have seen increased death rates. Vaccinations One major factor contributing to the decrease in death rates for many diseases since the year 1900 is the introduction of vaccinations. The decrease seen in the rates of death due to pneumonia and influenza is a prime example of this. In 1900, pneumonia and influenza were the leading causes of death, with around 202 deaths per 100,000 population. However, in 2023 pneumonia and influenza were not even among the ten leading causes of death. Cancer One disease that has seen a large increase in death rates since 1900 is cancer. Cancer currently accounts for almost 20 percent of all deaths in the United States, with death rates among men higher than those for women. The deadliest form of cancer for both men and women is cancer of the lung and bronchus. Some of the most common avoidable risk factors for cancer include smoking, drinking alcohol, sun exposure, and obesity.

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/non-re...

Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) in North America was reported at 13.17 % in 2019, according to the World Bank collection of development indicators, compiled from officially recognized sources. North America - Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 - actual values, historical data, forecasts and projections were sourced from the World Bank on September of 2025.